Thiogenesis Therapeutics Corp. (TTI : TSX-V)
Common Stock
$0.53
CAD
+0.00 (%)
Last updated: 2026-07-16
TTI
Thiogenesis Therapeutics Corp.
WealthAwesomePerformance
1 Day
+0.00%
1 Week
-7.02%
1 Month
-7.02%
YTD
-18.46%
Key Statistics
Market Cap
$27.47M
52W High
$0.87
52W Low
$0.44
P/E Ratio
-
50 Day MA
$0.57
200 Day MA
$0.59
Beta
0.57
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/16/2026 | $0.53 | $0.53 | $0.53 | $0.53 | $0.53 | 500 |
| 7/15/2026 | $0.56 | $0.56 | $0.53 | $0.53 | $0.53 | 5,500 |
| 7/14/2026 | $0.57 | $0.57 | $0.57 | $0.57 | $0.57 | 500 |
| 7/10/2026 | $0.57 | $0.57 | $0.56 | $0.56 | $0.56 | 16,500 |
| 7/3/2026 | $0.57 | $0.57 | $0.57 | $0.57 | $0.57 | 500 |
| 7/2/2026 | $0.54 | $0.54 | $0.54 | $0.54 | $0.54 | 0 |
| 6/30/2026 | $0.54 | $0.54 | $0.54 | $0.54 | $0.54 | 0 |
| 6/29/2026 | $0.54 | $0.54 | $0.54 | $0.54 | $0.54 | 3,500 |
| 6/26/2026 | $0.54 | $0.54 | $0.54 | $0.54 | $0.54 | 10,500 |
| 6/25/2026 | $0.57 | $0.57 | $0.55 | $0.55 | $0.55 | 3,500 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TTI's historical volatility
30-Day Vol
38.4%
Annualized
90-Day Vol
69.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.50 | C$0.44 – C$0.57 |
| 60 trading days | C$0.47 | C$0.39 – C$0.57 |
| 90 trading days | C$0.44 | C$0.35 – C$0.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -724.21%
- EPS (Diluted)
- -0.14
- Book Value
- -0.00
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About TTI
Articles Featuring TTI.V
Latest articles and analysis covering TTI.V
